Abstract 5383
Background
Cancer survivorship is increasing yet cancer treatment can cause de-conditioning and reduce physical capacity. Consequently there is a need to identify interventions which can improve health. This study investigated the impact of a personalised self-management programme on the physical and psychological health of cancer survivors with lifestyle related health risks.
Methods
For the purpose of this research the Moving on Programme was developed which is an intervention for cancer survivors to self-manage lifestyle. A randomised control pilot trial was conducted on 123 cancer survivors with a BMI > 25. Participants were randomly assigned to the control (n = 61) or intervention (n = 62) groups. The intervention group attended the Moving on Programme and engaged in personalised goal-setting to incrementally increase physical activity and made dietary changes. Participants in the control group received only brief standard advice. Objective measures of health behaviour were collected via Fitbit. Data on anthropometric, physiological, dietary behaviour and psychological measures were collected on all participants at baseline, three and six months. A sample of participants were interviewed (n = 13) to examine acceptability of the intervention.
Results
Overall, the results demonstrate a positive effect of the Moving on Programme. There was a significant reduction in BMI observed within the intervention group (p = 0.05) in the first three months. Positive participant outcomes also included improvement in physical and psychological wellbeing, and social functioning with reduced fatigue. Qualitative data demonstrated the acceptability of the intervention and participants identified that the Moving on Programme fulfils a deficit that exists in cancer survivorship and rehabilitation.
Conclusions
The Moving on Programme designed for this study, demonstrated physical and psychological benefits to participants. The use of behaviour change techniques and mobile technology was used effectively as an acceptable intervention that supports weight loss, promotes healthier behaviours and improves wellbeing in cancer survivors.
Clinical trial identification
ISRCTN18676721 https://doi.org/10.1186/ISRCTN18676721.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Irish Cancer Society.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5071 - Expression of estrogen receptor and programmed cell death-ligand 1 can be complementary prognostic factors in HPV-positive oropharyngeal squamous cell carcinoma
Presenter: Soohyeon Kwon
Session: Poster Display session 3
Resources:
Abstract
5306 - Real-world data of clinicopathologic characteristics of young oropharyngeal cancer patients.
Presenter: Maria Nieva
Session: Poster Display session 3
Resources:
Abstract
3407 - The clinical significance and biological mechanisms of miR-499a in high-tobacco exposed head and neck squamous cell carcinoma
Presenter: Shiqi Gong
Session: Poster Display session 3
Resources:
Abstract
3310 - Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic squamous cell carcinoma of the head and neck
Presenter: Rachel Galot
Session: Poster Display session 3
Resources:
Abstract
2362 - Blood-based testing of mutations in patients with Head and neck squamous cell carcinoma (HNSCC) using highly sensitive SafeSEQ technology
Presenter: Florentia Fostira
Session: Poster Display session 3
Resources:
Abstract
4533 - The head and neck Lung Immune Prognostic Index (HN-LIPI): a prognostic Score for Immune Checkpoint Inhibitors (ICI) in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) patients.
Presenter: Ruth Gabriela Herrera Gomez
Session: Poster Display session 3
Resources:
Abstract
5262 - Immune-related adverse events (irAEs) and outcome in recurrent/metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) patients (pts) treated by immune-checkpoints inhibitors (ICI)
Presenter: Neus Baste Rotllan
Session: Poster Display session 3
Resources:
Abstract
3725 - Intratumoral and peripheral exploratory biomarker analysis in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC) treated with RM-1929 photoimmunotherapy
Presenter: Jack Bui
Session: Poster Display session 3
Resources:
Abstract
2533 - A nomogram based prognostic score to predict overall survival (OS) in recurrent-metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts) treated with immune checkpoint inhibitors (ICI).
Presenter: Luay Mousa
Session: Poster Display session 3
Resources:
Abstract
2929 - Changes of the Commensal Microbiome during Treatment are Associated with Clinical Response in the Nasopharyngeal Carcinoma Patients
Presenter: Tingting Huang
Session: Poster Display session 3
Resources:
Abstract